The organization also granted priority review, breakthrough designation, and orphan drug designation to the application.
Non-Small Cell Lung Cancer
Advertisement
Mariano Provencio, MD, PhD, presented the results of CheckMate 77T as a late-breaking abstract at ASCO 2025.
Phase 2 of the study investigated the targeted therapy in treatment-naive patients with stage III ALK-positive disease.
Patrick M. Forde, MD, presented the late-breaking abstract during an oral abstract session at the 2025 ASCO Annual Meeting.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Researchers tested Dato-DXd for safety and tolerability in patients with advanced NSCLC.
Efficacy results, safety data, and survival data from the phase 2 study were presented at the ASCO 2025 Annual Meeting.
Ivonescimab plus chemotherapy “demonstrated a statistically significant and clinically meaningful improvement” in PFS.
Dr. Sanjay Juneja and Dr. Eric Singhi join a special episode of DDx for a candid conversation on a real patient case.
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Eric Singhi, MD, discusses the recent FDA approval and explains the associated new biomarker testing considerations.
Study Highlights Relationship Between Lipid Metabolism, NK Cells in the NSCLC Tumor Microenvironment
Study investigators suggested there may be a “promising therapeutic strategy for advancing NK cell-based immunotherapy."
The accelerated approval is specifically for patients with high c-Met protein overexpression.
Advertisement
Expert Interviews
Advertisement
Section Editor
Stephen V. Liu, MDEditor | Associate Professor, Georgetown University
Advertisement
Latest News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.